Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | POLB | P06746 | 5/20 | 0.42 |
| ▸ | USP2 | O75604 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8829476 | 0.84 | HSD17B10 (0.43) | HSD17B10MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL27432878 | 0.83 | HSD17B10 (0.47) | HSD17B10MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL286999 | 0.83 | HSD17B10 (0.47) | HSD17B10MAPTALDH1A1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10496189 | 0.81 | HSD17B10 (0.46) | HSD17B10MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL16437815 | 0.79 | SMN1; SMN2 (0.37) | HSD17B10MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL114334 | 0.79 | MAPT (0.44) | HSD17B10MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL540823 | 0.79 | ALDH1A1 (0.45) | HSD17B10MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4528112 | 0.77 | HSD17B10 (0.37) | HSD17B10MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5960474 | 0.77 | SMN1; SMN2 (0.35) | HSD17B10MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL8615319 | 0.76 | HSD17B10 (0.43) | HSD17B10MAPTALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2021-09-21 | — | — | US | disclosed |
| CN-108369222-B | Opioid receptor modulators and uses thereof | 明尼苏达大学董事会 | 2021-06-04 | — | — | CN | disclosed |
| EP-3344997-B1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | UNIV MINNESOTA (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3344997-B1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | UNIV MINNESOTA (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2020-06-11 | — | — | US | disclosed |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2020-03-24 | — | — | US | disclosed |
| WO-2020033944-A2 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| EP-3218381-B1 | SPIRO-THIAZOLONES | HOFFMANN LA ROCHE (CH) | 2019-01-23 | — | — | EP | disclosed |
| US-20040092521-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-05-13 | — | — | US | disclosed |
| US-20020143025-A1 | Novel chain-breaking antioxidants | VANDERBILT UNIVERSITY | 2002-10-03 | — | — | US | disclosed |
| WO-2002000683-A2 | NOVEL CHAIN-BREAKING ANTIOXIDANTS | VANDERBILT UNIVERSITY (US) | 2002-01-03 | — | — | WO | disclosed |
| US-5747515-A | Heterocyclic compounds and compositions having nevropharmacological potential | ASTRA AKTIEBOLAG (SE) | 1998-05-05 | — | — | US | disclosed |
| US-5731335-A | NERVOUS SYSTEM DISORDERS; STROKE; ANTIISCHEMIC AGENTS; COGNITION ACTIVATORS | ASTRA AKTIEBOLAG (SE) | 1998-03-24 | — | — | US | disclosed |
| US-5607956-A | TREATMENT OF NEURODEGENERATIVE DISORDERS SUCH AS CEREBRAL ISCHEMIA, ALZHEIMER'S DISEASE | ASTRA AKTIEBOLAG (SE) | 1997-03-04 | — | — | US | disclosed |
| EP-0707573-A1 | NOVEL (1-PHENYL-1-HETEROCYCLYL)ALKANE DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE AGENTS | Astra Aktiebolag (SE) | 1996-04-24 | — | — | EP | disclosed |
| EP-0707584-A1 | NOVEL (1-HETEROAZOLYL-1-HETEROCYCLYL)ALKANE DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE AGENTS | Astra Aktiebolag (SE) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001967-A1 | NOVEL (1-PHENYL-1-HETEROCYCLYL)ALKANE DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE AGENTS | ASTRA AKTIEBOLAG (SE) | 1995-01-19 | — | — | WO | disclosed |
| WO-1995001979-A1 | NOVEL (1-HETEROAZOLYL-1-HETEROCYCLYL)ALKANE DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE AGENTS | ASTRA AKTIEBOLAG (SE) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | HSD17B10 800/4885MAPT 3/4885ALDH1A1 866/4885 |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | HSD17B10 800/4885MAPT 3/4885ALDH1A1 866/4885 |
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | HSD17B10 800/4885MAPT 3/4885ALDH1A1 866/4885 |
| US-20040092521-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | HSD17B10 2966/4885MAPT 3414/4885ALDH1A1 698/4885 |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | HSD17B10 800/4885MAPT 3/4885ALDH1A1 866/4885 |
| US-20020143025-A1 | Novel chain-breaking antioxidants | TTPA, GPX4, PNPO | HSD17B10 461/4885MAPT 3006/4885ALDH1A1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.